nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—PPP3CA—pons—malignant glioma	0.0262	0.126	CbGeAlD
Tacrolimus—PPP3CA—telencephalic ventricle—malignant glioma	0.0216	0.103	CbGeAlD
Tacrolimus—ORM1—vertebral column—malignant glioma	0.0135	0.0648	CbGeAlD
Tacrolimus—Sirolimus—FGF2—malignant glioma	0.0089	1	CrCbGaD
Tacrolimus—ABCA5—retina—malignant glioma	0.00833	0.0399	CbGeAlD
Tacrolimus—MTOR—blood vessel—malignant glioma	0.00788	0.0378	CbGeAlD
Tacrolimus—ABCA5—telencephalon—malignant glioma	0.00767	0.0367	CbGeAlD
Tacrolimus—ABCA5—medulla oblongata—malignant glioma	0.00602	0.0289	CbGeAlD
Tacrolimus—PPP3CA—brainstem—malignant glioma	0.00583	0.028	CbGeAlD
Tacrolimus—PPP3CA—retina—malignant glioma	0.00563	0.027	CbGeAlD
Tacrolimus—ABCA5—midbrain—malignant glioma	0.00551	0.0264	CbGeAlD
Tacrolimus—ABCA5—spinal cord—malignant glioma	0.00537	0.0257	CbGeAlD
Tacrolimus—PPP3CA—telencephalon—malignant glioma	0.00518	0.0248	CbGeAlD
Tacrolimus—MTOR—embryo—malignant glioma	0.0047	0.0225	CbGeAlD
Tacrolimus—ABCA5—central nervous system—malignant glioma	0.00436	0.0209	CbGeAlD
Tacrolimus—MTOR—brainstem—malignant glioma	0.00431	0.0207	CbGeAlD
Tacrolimus—ABCA5—cerebellum—malignant glioma	0.00426	0.0204	CbGeAlD
Tacrolimus—MTOR—retina—malignant glioma	0.00416	0.0199	CbGeAlD
Tacrolimus—PPP3CA—medulla oblongata—malignant glioma	0.00407	0.0195	CbGeAlD
Tacrolimus—MTOR—telencephalon—malignant glioma	0.00382	0.0183	CbGeAlD
Tacrolimus—FKBP1A—retina—malignant glioma	0.00374	0.0179	CbGeAlD
Tacrolimus—PPP3CA—midbrain—malignant glioma	0.00372	0.0178	CbGeAlD
Tacrolimus—PPP3CA—spinal cord—malignant glioma	0.00363	0.0174	CbGeAlD
Tacrolimus—ABCA5—brain—malignant glioma	0.00346	0.0166	CbGeAlD
Tacrolimus—FKBP1A—telencephalon—malignant glioma	0.00344	0.0165	CbGeAlD
Tacrolimus—PPP3CA—central nervous system—malignant glioma	0.00294	0.0141	CbGeAlD
Tacrolimus—PPP3CA—cerebellum—malignant glioma	0.00288	0.0138	CbGeAlD
Tacrolimus—FKBP1A—medulla oblongata—malignant glioma	0.0027	0.013	CbGeAlD
Tacrolimus—MTOR—spinal cord—malignant glioma	0.00268	0.0128	CbGeAlD
Tacrolimus—Burning sensation—Carmustine—malignant glioma	0.00257	0.00689	CcSEcCtD
Tacrolimus—Interstitial lung disease—Carmustine—malignant glioma	0.00252	0.00676	CcSEcCtD
Tacrolimus—Thrombosis—Carmustine—malignant glioma	0.00252	0.00676	CcSEcCtD
Tacrolimus—FKBP1A—midbrain—malignant glioma	0.00247	0.0118	CbGeAlD
Tacrolimus—Lung disorder—Temozolomide—malignant glioma	0.00243	0.00654	CcSEcCtD
Tacrolimus—Interstitial lung disease—Temozolomide—malignant glioma	0.00243	0.00654	CcSEcCtD
Tacrolimus—Influenza-like symptoms—Temozolomide—malignant glioma	0.00241	0.00648	CcSEcCtD
Tacrolimus—FKBP1A—spinal cord—malignant glioma	0.00241	0.0116	CbGeAlD
Tacrolimus—Stupor—Carmustine—malignant glioma	0.00239	0.00641	CcSEcCtD
Tacrolimus—PPP3CA—brain—malignant glioma	0.00234	0.0112	CbGeAlD
Tacrolimus—Hepatotoxicity—Carmustine—malignant glioma	0.00231	0.0062	CcSEcCtD
Tacrolimus—Herpes zoster—Temozolomide—malignant glioma	0.00229	0.00614	CcSEcCtD
Tacrolimus—Cholestasis—Temozolomide—malignant glioma	0.00227	0.00609	CcSEcCtD
Tacrolimus—Abscess—Carmustine—malignant glioma	0.00225	0.00605	CcSEcCtD
Tacrolimus—Hepatotoxicity—Temozolomide—malignant glioma	0.00223	0.00599	CcSEcCtD
Tacrolimus—Otitis media—Temozolomide—malignant glioma	0.00221	0.00594	CcSEcCtD
Tacrolimus—Coagulopathy—Temozolomide—malignant glioma	0.00221	0.00594	CcSEcCtD
Tacrolimus—Hyperaesthesia—Temozolomide—malignant glioma	0.00219	0.0059	CcSEcCtD
Tacrolimus—MTOR—central nervous system—malignant glioma	0.00217	0.0104	CbGeAlD
Tacrolimus—MTOR—cerebellum—malignant glioma	0.00212	0.0102	CbGeAlD
Tacrolimus—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00209	0.00562	CcSEcCtD
Tacrolimus—Endocrine disorder—Temozolomide—malignant glioma	0.00208	0.00558	CcSEcCtD
Tacrolimus—Speech disorder—Carmustine—malignant glioma	0.00207	0.00557	CcSEcCtD
Tacrolimus—Liver injury—Temozolomide—malignant glioma	0.00205	0.0055	CcSEcCtD
Tacrolimus—Accidental injury—Carmustine—malignant glioma	0.00201	0.00541	CcSEcCtD
Tacrolimus—Speech disorder—Temozolomide—malignant glioma	0.002	0.00538	CcSEcCtD
Tacrolimus—FKBP1A—central nervous system—malignant glioma	0.00196	0.00937	CbGeAlD
Tacrolimus—Thinking abnormal—Carmustine—malignant glioma	0.00195	0.00523	CcSEcCtD
Tacrolimus—FKBP1A—cerebellum—malignant glioma	0.00191	0.00916	CbGeAlD
Tacrolimus—Leukocytosis—Carmustine—malignant glioma	0.0019	0.00509	CcSEcCtD
Tacrolimus—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.00189	0.00509	CcSEcCtD
Tacrolimus—ORM1—spinal cord—malignant glioma	0.00189	0.00904	CbGeAlD
Tacrolimus—Herpes simplex—Temozolomide—malignant glioma	0.00187	0.00502	CcSEcCtD
Tacrolimus—Coordination abnormal—Carmustine—malignant glioma	0.00181	0.00488	CcSEcCtD
Tacrolimus—Hearing impaired—Temozolomide—malignant glioma	0.00181	0.00486	CcSEcCtD
Tacrolimus—Neck pain—Carmustine—malignant glioma	0.0018	0.00485	CcSEcCtD
Tacrolimus—Coordination abnormal—Temozolomide—malignant glioma	0.00175	0.00471	CcSEcCtD
Tacrolimus—Respiratory failure—Temozolomide—malignant glioma	0.00175	0.00471	CcSEcCtD
Tacrolimus—MTOR—brain—malignant glioma	0.00173	0.00827	CbGeAlD
Tacrolimus—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00172	0.00463	CcSEcCtD
Tacrolimus—Vaginal inflammation—Temozolomide—malignant glioma	0.00172	0.00463	CcSEcCtD
Tacrolimus—Urinary incontinence—Carmustine—malignant glioma	0.00172	0.00462	CcSEcCtD
Tacrolimus—Depressed level of consciousness—Carmustine—malignant glioma	0.00172	0.00462	CcSEcCtD
Tacrolimus—Candida infection—Carmustine—malignant glioma	0.0017	0.00457	CcSEcCtD
Tacrolimus—Neuropathy—Carmustine—malignant glioma	0.00167	0.0045	CcSEcCtD
Tacrolimus—Influenza like illness—Temozolomide—malignant glioma	0.00167	0.00449	CcSEcCtD
Tacrolimus—Urinary incontinence—Temozolomide—malignant glioma	0.00166	0.00447	CcSEcCtD
Tacrolimus—Depressed level of consciousness—Temozolomide—malignant glioma	0.00166	0.00447	CcSEcCtD
Tacrolimus—Candida infection—Temozolomide—malignant glioma	0.00164	0.00442	CcSEcCtD
Tacrolimus—ABCB1—blood vessel—malignant glioma	0.00164	0.00786	CbGeAlD
Tacrolimus—Coma—Carmustine—malignant glioma	0.00163	0.00437	CcSEcCtD
Tacrolimus—Vaginal infection—Temozolomide—malignant glioma	0.00163	0.00437	CcSEcCtD
Tacrolimus—Neuropathy—Temozolomide—malignant glioma	0.00162	0.00434	CcSEcCtD
Tacrolimus—Neoplasm—Carmustine—malignant glioma	0.00161	0.00433	CcSEcCtD
Tacrolimus—Dry eye—Temozolomide—malignant glioma	0.00159	0.00427	CcSEcCtD
Tacrolimus—Neoplasm—Temozolomide—malignant glioma	0.00156	0.00418	CcSEcCtD
Tacrolimus—Abnormal vision—Carmustine—malignant glioma	0.00155	0.00418	CcSEcCtD
Tacrolimus—FKBP1A—brain—malignant glioma	0.00155	0.00744	CbGeAlD
Tacrolimus—Sepsis—Carmustine—malignant glioma	0.00155	0.00415	CcSEcCtD
Tacrolimus—Mental disability—Carmustine—malignant glioma	0.00155	0.00415	CcSEcCtD
Tacrolimus—ORM1—central nervous system—malignant glioma	0.00153	0.00734	CbGeAlD
Tacrolimus—Abnormal vision—Temozolomide—malignant glioma	0.0015	0.00404	CcSEcCtD
Tacrolimus—Phlebitis—Carmustine—malignant glioma	0.0015	0.00403	CcSEcCtD
Tacrolimus—Mental disability—Temozolomide—malignant glioma	0.00149	0.00402	CcSEcCtD
Tacrolimus—Thrombophlebitis—Carmustine—malignant glioma	0.00149	0.00401	CcSEcCtD
Tacrolimus—Diabetes mellitus—Carmustine—malignant glioma	0.00149	0.004	CcSEcCtD
Tacrolimus—Ear pain—Temozolomide—malignant glioma	0.00147	0.00394	CcSEcCtD
Tacrolimus—Thrombophlebitis—Temozolomide—malignant glioma	0.00144	0.00388	CcSEcCtD
Tacrolimus—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00144	0.00386	CcSEcCtD
Tacrolimus—Eye pain—Carmustine—malignant glioma	0.00143	0.00385	CcSEcCtD
Tacrolimus—Gastroenteritis—Temozolomide—malignant glioma	0.00141	0.00379	CcSEcCtD
Tacrolimus—Injury—Carmustine—malignant glioma	0.00141	0.00378	CcSEcCtD
Tacrolimus—Deafness—Temozolomide—malignant glioma	0.0014	0.00375	CcSEcCtD
Tacrolimus—Hepatic failure—Temozolomide—malignant glioma	0.00139	0.00374	CcSEcCtD
Tacrolimus—Eye pain—Temozolomide—malignant glioma	0.00138	0.00372	CcSEcCtD
Tacrolimus—Amnesia—Carmustine—malignant glioma	0.00138	0.0037	CcSEcCtD
Tacrolimus—Nasal congestion—Temozolomide—malignant glioma	0.00137	0.00369	CcSEcCtD
Tacrolimus—Hot flush—Temozolomide—malignant glioma	0.00134	0.00359	CcSEcCtD
Tacrolimus—Amnesia—Temozolomide—malignant glioma	0.00133	0.00357	CcSEcCtD
Tacrolimus—Dermatitis exfoliative—Temozolomide—malignant glioma	0.00133	0.00356	CcSEcCtD
Tacrolimus—Menopausal symptoms—Temozolomide—malignant glioma	0.00133	0.00356	CcSEcCtD
Tacrolimus—Thirst—Temozolomide—malignant glioma	0.00131	0.00353	CcSEcCtD
Tacrolimus—Hyponatraemia—Carmustine—malignant glioma	0.0013	0.00349	CcSEcCtD
Tacrolimus—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00129	0.00348	CcSEcCtD
Tacrolimus—Face oedema—Carmustine—malignant glioma	0.00125	0.00336	CcSEcCtD
Tacrolimus—Affect lability—Temozolomide—malignant glioma	0.00123	0.00331	CcSEcCtD
Tacrolimus—Face oedema—Temozolomide—malignant glioma	0.00121	0.00324	CcSEcCtD
Tacrolimus—Liver function test abnormal—Carmustine—malignant glioma	0.00119	0.00321	CcSEcCtD
Tacrolimus—Mood swings—Temozolomide—malignant glioma	0.00118	0.00318	CcSEcCtD
Tacrolimus—Hypokalaemia—Carmustine—malignant glioma	0.00118	0.00316	CcSEcCtD
Tacrolimus—Dehydration—Temozolomide—malignant glioma	0.00116	0.00312	CcSEcCtD
Tacrolimus—Dry skin—Temozolomide—malignant glioma	0.00115	0.00308	CcSEcCtD
Tacrolimus—Muscular weakness—Carmustine—malignant glioma	0.00114	0.00307	CcSEcCtD
Tacrolimus—Hypokalaemia—Temozolomide—malignant glioma	0.00114	0.00306	CcSEcCtD
Tacrolimus—Breast disorder—Temozolomide—malignant glioma	0.00113	0.00304	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.00113	0.00302	CcSEcCtD
Tacrolimus—Dysphagia—Carmustine—malignant glioma	0.00112	0.003	CcSEcCtD
Tacrolimus—Muscular weakness—Temozolomide—malignant glioma	0.0011	0.00296	CcSEcCtD
Tacrolimus—Abdominal distension—Temozolomide—malignant glioma	0.00109	0.00292	CcSEcCtD
Tacrolimus—Dysphagia—Temozolomide—malignant glioma	0.00108	0.0029	CcSEcCtD
Tacrolimus—ALB—brain—malignant glioma	0.00107	0.00511	CbGeAlD
Tacrolimus—Pancytopenia—Carmustine—malignant glioma	0.00106	0.00285	CcSEcCtD
Tacrolimus—Sweating increased—Temozolomide—malignant glioma	0.00105	0.00283	CcSEcCtD
Tacrolimus—Neutropenia—Carmustine—malignant glioma	0.00105	0.00281	CcSEcCtD
Tacrolimus—Bronchitis—Temozolomide—malignant glioma	0.00104	0.00279	CcSEcCtD
Tacrolimus—Pancytopenia—Temozolomide—malignant glioma	0.00103	0.00276	CcSEcCtD
Tacrolimus—Dysuria—Temozolomide—malignant glioma	0.00101	0.00271	CcSEcCtD
Tacrolimus—Neutropenia—Temozolomide—malignant glioma	0.00101	0.00271	CcSEcCtD
Tacrolimus—Hyperglycaemia—Carmustine—malignant glioma	0.00101	0.00271	CcSEcCtD
Tacrolimus—Pneumonia—Carmustine—malignant glioma	0.001	0.00269	CcSEcCtD
Tacrolimus—Pollakiuria—Temozolomide—malignant glioma	0.000998	0.00268	CcSEcCtD
Tacrolimus—Depression—Carmustine—malignant glioma	0.000994	0.00267	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Temozolomide—malignant glioma	0.000986	0.00265	CcSEcCtD
Tacrolimus—Weight increased—Temozolomide—malignant glioma	0.000983	0.00264	CcSEcCtD
Tacrolimus—Renal failure—Carmustine—malignant glioma	0.00098	0.00263	CcSEcCtD
Tacrolimus—ABCB1—embryo—malignant glioma	0.000979	0.00469	CbGeAlD
Tacrolimus—Weight decreased—Temozolomide—malignant glioma	0.000978	0.00263	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Carmustine—malignant glioma	0.000977	0.00263	CcSEcCtD
Tacrolimus—Hyperglycaemia—Temozolomide—malignant glioma	0.000975	0.00262	CcSEcCtD
Tacrolimus—Stomatitis—Carmustine—malignant glioma	0.000972	0.00261	CcSEcCtD
Tacrolimus—Urinary tract infection—Carmustine—malignant glioma	0.000969	0.0026	CcSEcCtD
Tacrolimus—Pneumonia—Temozolomide—malignant glioma	0.000969	0.0026	CcSEcCtD
Tacrolimus—Infestation—Temozolomide—malignant glioma	0.000964	0.00259	CcSEcCtD
Tacrolimus—Infestation NOS—Temozolomide—malignant glioma	0.000964	0.00259	CcSEcCtD
Tacrolimus—Depression—Temozolomide—malignant glioma	0.000961	0.00258	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000955	0.00257	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Temozolomide—malignant glioma	0.000944	0.00254	CcSEcCtD
Tacrolimus—Stomatitis—Temozolomide—malignant glioma	0.000939	0.00252	CcSEcCtD
Tacrolimus—Urinary tract infection—Temozolomide—malignant glioma	0.000937	0.00252	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Temozolomide—malignant glioma	0.000911	0.00245	CcSEcCtD
Tacrolimus—Sinusitis—Temozolomide—malignant glioma	0.000904	0.00243	CcSEcCtD
Tacrolimus—Haemoglobin—Carmustine—malignant glioma	0.0009	0.00242	CcSEcCtD
Tacrolimus—Haemorrhage—Carmustine—malignant glioma	0.000895	0.0024	CcSEcCtD
Tacrolimus—Hypoaesthesia—Carmustine—malignant glioma	0.000891	0.00239	CcSEcCtD
Tacrolimus—Hallucination—Carmustine—malignant glioma	0.000891	0.00239	CcSEcCtD
Tacrolimus—Oedema peripheral—Carmustine—malignant glioma	0.000882	0.00237	CcSEcCtD
Tacrolimus—Connective tissue disorder—Carmustine—malignant glioma	0.00088	0.00236	CcSEcCtD
Tacrolimus—Haemoglobin—Temozolomide—malignant glioma	0.000869	0.00234	CcSEcCtD
Tacrolimus—ABCB1—retina—malignant glioma	0.000865	0.00415	CbGeAlD
Tacrolimus—Hepatitis—Temozolomide—malignant glioma	0.000865	0.00232	CcSEcCtD
Tacrolimus—Haemorrhage—Temozolomide—malignant glioma	0.000865	0.00232	CcSEcCtD
Tacrolimus—Visual impairment—Carmustine—malignant glioma	0.000863	0.00232	CcSEcCtD
Tacrolimus—Hypoaesthesia—Temozolomide—malignant glioma	0.000861	0.00231	CcSEcCtD
Tacrolimus—Hallucination—Temozolomide—malignant glioma	0.000861	0.00231	CcSEcCtD
Tacrolimus—Pharyngitis—Temozolomide—malignant glioma	0.000858	0.00231	CcSEcCtD
Tacrolimus—Urinary tract disorder—Temozolomide—malignant glioma	0.000854	0.00229	CcSEcCtD
Tacrolimus—Oedema peripheral—Temozolomide—malignant glioma	0.000852	0.00229	CcSEcCtD
Tacrolimus—Connective tissue disorder—Temozolomide—malignant glioma	0.00085	0.00228	CcSEcCtD
Tacrolimus—Urethral disorder—Temozolomide—malignant glioma	0.000848	0.00228	CcSEcCtD
Tacrolimus—Eye disorder—Carmustine—malignant glioma	0.000836	0.00225	CcSEcCtD
Tacrolimus—Visual impairment—Temozolomide—malignant glioma	0.000834	0.00224	CcSEcCtD
Tacrolimus—Flushing—Carmustine—malignant glioma	0.000831	0.00223	CcSEcCtD
Tacrolimus—Erythema multiforme—Temozolomide—malignant glioma	0.000818	0.0022	CcSEcCtD
Tacrolimus—Eye disorder—Temozolomide—malignant glioma	0.000808	0.00217	CcSEcCtD
Tacrolimus—Tinnitus—Temozolomide—malignant glioma	0.000806	0.00217	CcSEcCtD
Tacrolimus—Cardiac disorder—Temozolomide—malignant glioma	0.000803	0.00216	CcSEcCtD
Tacrolimus—Flushing—Temozolomide—malignant glioma	0.000803	0.00216	CcSEcCtD
Tacrolimus—Arrhythmia—Carmustine—malignant glioma	0.0008	0.00215	CcSEcCtD
Tacrolimus—ABCB1—telencephalon—malignant glioma	0.000796	0.00381	CbGeAlD
Tacrolimus—Alopecia—Carmustine—malignant glioma	0.000791	0.00212	CcSEcCtD
Tacrolimus—Angiopathy—Temozolomide—malignant glioma	0.000785	0.00211	CcSEcCtD
Tacrolimus—Mental disorder—Carmustine—malignant glioma	0.000784	0.00211	CcSEcCtD
Tacrolimus—Immune system disorder—Temozolomide—malignant glioma	0.000781	0.0021	CcSEcCtD
Tacrolimus—Mediastinal disorder—Temozolomide—malignant glioma	0.00078	0.00209	CcSEcCtD
Tacrolimus—Malnutrition—Carmustine—malignant glioma	0.000779	0.00209	CcSEcCtD
Tacrolimus—Erythema—Carmustine—malignant glioma	0.000779	0.00209	CcSEcCtD
Tacrolimus—Chills—Temozolomide—malignant glioma	0.000776	0.00208	CcSEcCtD
Tacrolimus—Alopecia—Temozolomide—malignant glioma	0.000764	0.00205	CcSEcCtD
Tacrolimus—Mental disorder—Temozolomide—malignant glioma	0.000758	0.00204	CcSEcCtD
Tacrolimus—Back pain—Carmustine—malignant glioma	0.000754	0.00202	CcSEcCtD
Tacrolimus—Malnutrition—Temozolomide—malignant glioma	0.000753	0.00202	CcSEcCtD
Tacrolimus—Erythema—Temozolomide—malignant glioma	0.000753	0.00202	CcSEcCtD
Tacrolimus—Dysgeusia—Temozolomide—malignant glioma	0.000737	0.00198	CcSEcCtD
Tacrolimus—Vision blurred—Carmustine—malignant glioma	0.000734	0.00197	CcSEcCtD
Tacrolimus—Tremor—Carmustine—malignant glioma	0.00073	0.00196	CcSEcCtD
Tacrolimus—Back pain—Temozolomide—malignant glioma	0.000728	0.00196	CcSEcCtD
Tacrolimus—Anaemia—Carmustine—malignant glioma	0.00072	0.00193	CcSEcCtD
Tacrolimus—Agitation—Carmustine—malignant glioma	0.000716	0.00192	CcSEcCtD
Tacrolimus—Vision blurred—Temozolomide—malignant glioma	0.00071	0.00191	CcSEcCtD
Tacrolimus—Tremor—Temozolomide—malignant glioma	0.000705	0.0019	CcSEcCtD
Tacrolimus—Ill-defined disorder—Temozolomide—malignant glioma	0.000699	0.00188	CcSEcCtD
Tacrolimus—Leukopenia—Carmustine—malignant glioma	0.000697	0.00187	CcSEcCtD
Tacrolimus—Anaemia—Temozolomide—malignant glioma	0.000696	0.00187	CcSEcCtD
Tacrolimus—Agitation—Temozolomide—malignant glioma	0.000692	0.00186	CcSEcCtD
Tacrolimus—Malaise—Temozolomide—malignant glioma	0.000679	0.00182	CcSEcCtD
Tacrolimus—Vertigo—Temozolomide—malignant glioma	0.000676	0.00182	CcSEcCtD
Tacrolimus—Convulsion—Carmustine—malignant glioma	0.000675	0.00181	CcSEcCtD
Tacrolimus—Leukopenia—Temozolomide—malignant glioma	0.000674	0.00181	CcSEcCtD
Tacrolimus—Hypertension—Carmustine—malignant glioma	0.000673	0.00181	CcSEcCtD
Tacrolimus—Palpitations—Temozolomide—malignant glioma	0.000665	0.00179	CcSEcCtD
Tacrolimus—Chest pain—Carmustine—malignant glioma	0.000663	0.00178	CcSEcCtD
Tacrolimus—Myalgia—Carmustine—malignant glioma	0.000663	0.00178	CcSEcCtD
Tacrolimus—Anxiety—Carmustine—malignant glioma	0.000661	0.00178	CcSEcCtD
Tacrolimus—Cough—Temozolomide—malignant glioma	0.000657	0.00177	CcSEcCtD
Tacrolimus—Convulsion—Temozolomide—malignant glioma	0.000652	0.00175	CcSEcCtD
Tacrolimus—Hypertension—Temozolomide—malignant glioma	0.00065	0.00175	CcSEcCtD
Tacrolimus—Confusional state—Carmustine—malignant glioma	0.000641	0.00172	CcSEcCtD
Tacrolimus—Arthralgia—Temozolomide—malignant glioma	0.000641	0.00172	CcSEcCtD
Tacrolimus—Myalgia—Temozolomide—malignant glioma	0.000641	0.00172	CcSEcCtD
Tacrolimus—CYP3A4—central nervous system—malignant glioma	0.000639	0.00306	CbGeAlD
Tacrolimus—Anxiety—Temozolomide—malignant glioma	0.000639	0.00172	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000637	0.00171	CcSEcCtD
Tacrolimus—Oedema—Carmustine—malignant glioma	0.000636	0.00171	CcSEcCtD
Tacrolimus—Discomfort—Temozolomide—malignant glioma	0.000633	0.0017	CcSEcCtD
Tacrolimus—Infection—Carmustine—malignant glioma	0.000632	0.0017	CcSEcCtD
Tacrolimus—Dry mouth—Temozolomide—malignant glioma	0.000627	0.00168	CcSEcCtD
Tacrolimus—ABCB1—medulla oblongata—malignant glioma	0.000625	0.003	CbGeAlD
Tacrolimus—Thrombocytopenia—Carmustine—malignant glioma	0.000623	0.00167	CcSEcCtD
Tacrolimus—Tachycardia—Carmustine—malignant glioma	0.000621	0.00167	CcSEcCtD
Tacrolimus—Confusional state—Temozolomide—malignant glioma	0.00062	0.00166	CcSEcCtD
Tacrolimus—Anaphylactic shock—Temozolomide—malignant glioma	0.000615	0.00165	CcSEcCtD
Tacrolimus—Oedema—Temozolomide—malignant glioma	0.000615	0.00165	CcSEcCtD
Tacrolimus—Infection—Temozolomide—malignant glioma	0.00061	0.00164	CcSEcCtD
Tacrolimus—Anorexia—Carmustine—malignant glioma	0.000606	0.00163	CcSEcCtD
Tacrolimus—Nervous system disorder—Temozolomide—malignant glioma	0.000603	0.00162	CcSEcCtD
Tacrolimus—Thrombocytopenia—Temozolomide—malignant glioma	0.000602	0.00162	CcSEcCtD
Tacrolimus—Skin disorder—Temozolomide—malignant glioma	0.000597	0.0016	CcSEcCtD
Tacrolimus—Hypotension—Carmustine—malignant glioma	0.000594	0.0016	CcSEcCtD
Tacrolimus—Hyperhidrosis—Temozolomide—malignant glioma	0.000594	0.0016	CcSEcCtD
Tacrolimus—Anorexia—Temozolomide—malignant glioma	0.000586	0.00157	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000579	0.00156	CcSEcCtD
Tacrolimus—Insomnia—Carmustine—malignant glioma	0.000575	0.00155	CcSEcCtD
Tacrolimus—ABCB1—midbrain—malignant glioma	0.000571	0.00274	CbGeAlD
Tacrolimus—Paraesthesia—Carmustine—malignant glioma	0.000571	0.00153	CcSEcCtD
Tacrolimus—Dyspnoea—Carmustine—malignant glioma	0.000567	0.00152	CcSEcCtD
Tacrolimus—Somnolence—Carmustine—malignant glioma	0.000565	0.00152	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00056	0.0015	CcSEcCtD
Tacrolimus—ABCB1—spinal cord—malignant glioma	0.000558	0.00267	CbGeAlD
Tacrolimus—Insomnia—Temozolomide—malignant glioma	0.000556	0.00149	CcSEcCtD
Tacrolimus—Decreased appetite—Carmustine—malignant glioma	0.000553	0.00148	CcSEcCtD
Tacrolimus—Paraesthesia—Temozolomide—malignant glioma	0.000552	0.00148	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Carmustine—malignant glioma	0.000549	0.00147	CcSEcCtD
Tacrolimus—Dyspnoea—Temozolomide—malignant glioma	0.000548	0.00147	CcSEcCtD
Tacrolimus—Somnolence—Temozolomide—malignant glioma	0.000546	0.00147	CcSEcCtD
Tacrolimus—Constipation—Carmustine—malignant glioma	0.000544	0.00146	CcSEcCtD
Tacrolimus—Pain—Carmustine—malignant glioma	0.000544	0.00146	CcSEcCtD
Tacrolimus—Dyspepsia—Temozolomide—malignant glioma	0.000541	0.00145	CcSEcCtD
Tacrolimus—Decreased appetite—Temozolomide—malignant glioma	0.000534	0.00144	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000531	0.00143	CcSEcCtD
Tacrolimus—Fatigue—Temozolomide—malignant glioma	0.00053	0.00142	CcSEcCtD
Tacrolimus—Pain—Temozolomide—malignant glioma	0.000525	0.00141	CcSEcCtD
Tacrolimus—Constipation—Temozolomide—malignant glioma	0.000525	0.00141	CcSEcCtD
Tacrolimus—Feeling abnormal—Carmustine—malignant glioma	0.000524	0.00141	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Carmustine—malignant glioma	0.00052	0.0014	CcSEcCtD
Tacrolimus—Feeling abnormal—Temozolomide—malignant glioma	0.000506	0.00136	CcSEcCtD
Tacrolimus—Abdominal pain—Carmustine—malignant glioma	0.000503	0.00135	CcSEcCtD
Tacrolimus—Body temperature increased—Carmustine—malignant glioma	0.000503	0.00135	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Temozolomide—malignant glioma	0.000502	0.00135	CcSEcCtD
Tacrolimus—Urticaria—Temozolomide—malignant glioma	0.000488	0.00131	CcSEcCtD
Tacrolimus—Abdominal pain—Temozolomide—malignant glioma	0.000486	0.0013	CcSEcCtD
Tacrolimus—Body temperature increased—Temozolomide—malignant glioma	0.000486	0.0013	CcSEcCtD
Tacrolimus—Hypersensitivity—Carmustine—malignant glioma	0.000468	0.00126	CcSEcCtD
Tacrolimus—Asthenia—Carmustine—malignant glioma	0.000456	0.00123	CcSEcCtD
Tacrolimus—Hypersensitivity—Temozolomide—malignant glioma	0.000453	0.00122	CcSEcCtD
Tacrolimus—ABCB1—central nervous system—malignant glioma	0.000452	0.00217	CbGeAlD
Tacrolimus—ABCB1—cerebellum—malignant glioma	0.000442	0.00212	CbGeAlD
Tacrolimus—Asthenia—Temozolomide—malignant glioma	0.000441	0.00118	CcSEcCtD
Tacrolimus—Diarrhoea—Carmustine—malignant glioma	0.000435	0.00117	CcSEcCtD
Tacrolimus—Pruritus—Temozolomide—malignant glioma	0.000435	0.00117	CcSEcCtD
Tacrolimus—Dizziness—Carmustine—malignant glioma	0.000421	0.00113	CcSEcCtD
Tacrolimus—Diarrhoea—Temozolomide—malignant glioma	0.00042	0.00113	CcSEcCtD
Tacrolimus—Dizziness—Temozolomide—malignant glioma	0.000406	0.00109	CcSEcCtD
Tacrolimus—Vomiting—Carmustine—malignant glioma	0.000404	0.00109	CcSEcCtD
Tacrolimus—Rash—Carmustine—malignant glioma	0.000401	0.00108	CcSEcCtD
Tacrolimus—Dermatitis—Carmustine—malignant glioma	0.000401	0.00108	CcSEcCtD
Tacrolimus—Headache—Carmustine—malignant glioma	0.000398	0.00107	CcSEcCtD
Tacrolimus—Vomiting—Temozolomide—malignant glioma	0.000391	0.00105	CcSEcCtD
Tacrolimus—Rash—Temozolomide—malignant glioma	0.000387	0.00104	CcSEcCtD
Tacrolimus—Dermatitis—Temozolomide—malignant glioma	0.000387	0.00104	CcSEcCtD
Tacrolimus—Headache—Temozolomide—malignant glioma	0.000385	0.00103	CcSEcCtD
Tacrolimus—Nausea—Carmustine—malignant glioma	0.000378	0.00101	CcSEcCtD
Tacrolimus—Nausea—Temozolomide—malignant glioma	0.000365	0.000981	CcSEcCtD
Tacrolimus—ABCB1—brain—malignant glioma	0.000359	0.00172	CbGeAlD
Tacrolimus—PPP3CA—Disease—PIK3CA—malignant glioma	3.18e-05	7.75e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGF—malignant glioma	3.18e-05	7.75e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MMP9—malignant glioma	3.17e-05	7.74e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	3.17e-05	7.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTPN11—malignant glioma	3.16e-05	7.7e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTEN—malignant glioma	3.16e-05	7.69e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—F2—malignant glioma	3.15e-05	7.67e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—FN1—malignant glioma	3.15e-05	7.67e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—STAT3—malignant glioma	3.12e-05	7.62e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—FGF2—malignant glioma	3.11e-05	7.58e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	3.1e-05	7.55e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AKT1—malignant glioma	3.08e-05	7.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—BAD—malignant glioma	3.06e-05	7.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOTCH1—malignant glioma	3.03e-05	7.4e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CG—malignant glioma	3.01e-05	7.34e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	3.01e-05	7.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTT1—malignant glioma	3e-05	7.31e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EGF—malignant glioma	2.98e-05	7.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP3—malignant glioma	2.98e-05	7.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD80—malignant glioma	2.97e-05	7.25e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—malignant glioma	2.97e-05	7.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—APC—malignant glioma	2.97e-05	7.24e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PTPN11—malignant glioma	2.96e-05	7.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN2B—malignant glioma	2.95e-05	7.19e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—IDH1—malignant glioma	2.95e-05	7.19e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	2.95e-05	7.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT2—malignant glioma	2.94e-05	7.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGF—malignant glioma	2.93e-05	7.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	2.93e-05	7.13e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTPN11—malignant glioma	2.92e-05	7.11e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MDM2—malignant glioma	2.91e-05	7.1e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MYC—malignant glioma	2.9e-05	7.08e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RAF1—malignant glioma	2.9e-05	7.07e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTP1—malignant glioma	2.87e-05	7.01e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ERBB2—malignant glioma	2.87e-05	7e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTK2—malignant glioma	2.87e-05	6.99e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SPHK1—malignant glioma	2.86e-05	6.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—malignant glioma	2.85e-05	6.95e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—malignant glioma	2.85e-05	6.95e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—malignant glioma	2.84e-05	6.92e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CB—malignant glioma	2.83e-05	6.9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CD—malignant glioma	2.83e-05	6.89e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STAT3—malignant glioma	2.82e-05	6.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HES1—malignant glioma	2.82e-05	6.86e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—malignant glioma	2.81e-05	6.86e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS1—malignant glioma	2.81e-05	6.85e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—malignant glioma	2.81e-05	6.84e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NCOR1—malignant glioma	2.8e-05	6.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CAT—malignant glioma	2.8e-05	6.82e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP2C18—malignant glioma	2.8e-05	6.82e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—BRAF—malignant glioma	2.79e-05	6.8e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ASMT—malignant glioma	2.79e-05	6.8e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT2—malignant glioma	2.76e-05	6.72e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	2.74e-05	6.69e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—PIK3CA—malignant glioma	2.73e-05	6.65e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL8—malignant glioma	2.72e-05	6.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT2—malignant glioma	2.72e-05	6.62e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—FGF2—malignant glioma	2.71e-05	6.6e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—malignant glioma	2.69e-05	6.57e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	2.69e-05	6.55e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—malignant glioma	2.68e-05	6.54e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PDGFRA—malignant glioma	2.68e-05	6.53e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CD—malignant glioma	2.65e-05	6.46e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	2.65e-05	6.45e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NCOR1—malignant glioma	2.64e-05	6.44e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—BCAN—malignant glioma	2.62e-05	6.39e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—malignant glioma	2.62e-05	6.39e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—BCHE—malignant glioma	2.61e-05	6.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CD—malignant glioma	2.61e-05	6.36e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CASP3—malignant glioma	2.6e-05	6.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SPP1—malignant glioma	2.6e-05	6.34e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—malignant glioma	2.6e-05	6.34e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	2.6e-05	6.34e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—malignant glioma	2.6e-05	6.33e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTT1—malignant glioma	2.58e-05	6.3e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SLC5A5—malignant glioma	2.58e-05	6.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PIK3CA—malignant glioma	2.58e-05	6.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—BCL2—malignant glioma	2.57e-05	6.26e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—malignant glioma	2.57e-05	6.25e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNG—malignant glioma	2.55e-05	6.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MDM2—malignant glioma	2.53e-05	6.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—RAF1—malignant glioma	2.52e-05	6.15e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FGF2—malignant glioma	2.5e-05	6.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ERBB2—malignant glioma	2.5e-05	6.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PIK3CA—malignant glioma	2.48e-05	6.04e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TERT—malignant glioma	2.47e-05	6.01e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PIK3CA—malignant glioma	2.47e-05	6.01e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CB—malignant glioma	2.46e-05	6.01e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—malignant glioma	2.46e-05	6e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTEN—malignant glioma	2.45e-05	5.97e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—malignant glioma	2.42e-05	5.91e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS1—malignant glioma	2.42e-05	5.9e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	2.41e-05	5.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PDGFB—malignant glioma	2.41e-05	5.87e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGFR1—malignant glioma	2.4e-05	5.84e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—RAF1—malignant glioma	2.36e-05	5.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HIF1A—malignant glioma	2.36e-05	5.75e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MDM2—malignant glioma	2.34e-05	5.7e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—RAF1—malignant glioma	2.33e-05	5.68e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CB—malignant glioma	2.31e-05	5.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERBB2—malignant glioma	2.3e-05	5.62e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CAV1—malignant glioma	2.28e-05	5.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CB—malignant glioma	2.27e-05	5.54e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1B—malignant glioma	2.27e-05	5.54e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTT1—malignant glioma	2.26e-05	5.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—malignant glioma	2.26e-05	5.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KDR—malignant glioma	2.26e-05	5.5e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—malignant glioma	2.25e-05	5.49e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—BCHE—malignant glioma	2.25e-05	5.48e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—malignant glioma	2.23e-05	5.44e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—malignant glioma	2.23e-05	5.43e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC5A5—malignant glioma	2.22e-05	5.42e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—malignant glioma	2.21e-05	5.39e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	2.2e-05	5.35e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—malignant glioma	2.19e-05	5.34e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FN1—malignant glioma	2.17e-05	5.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—F2—malignant glioma	2.17e-05	5.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CAV1—malignant glioma	2.15e-05	5.25e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—malignant glioma	2.15e-05	5.25e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BAD—malignant glioma	2.15e-05	5.23e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—malignant glioma	2.13e-05	5.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOTCH1—malignant glioma	2.13e-05	5.18e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS1—malignant glioma	2.12e-05	5.17e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—malignant glioma	2.12e-05	5.17e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—IDH2—malignant glioma	2.11e-05	5.15e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—malignant glioma	2.11e-05	5.13e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	2.1e-05	5.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CD80—malignant glioma	2.08e-05	5.08e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	2.08e-05	5.08e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APC—malignant glioma	2.08e-05	5.07e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CG—malignant glioma	2.08e-05	5.07e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTP1—malignant glioma	2.08e-05	5.07e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGF—malignant glioma	2.05e-05	5.01e-05	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—RAF1—malignant glioma	2.05e-05	4.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTPN11—malignant glioma	2.04e-05	4.98e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—malignant glioma	2.03e-05	4.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—malignant glioma	2.02e-05	4.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CAT—malignant glioma	2.02e-05	4.93e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—malignant glioma	2.01e-05	4.91e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—malignant glioma	1.99e-05	4.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2B6—malignant glioma	1.99e-05	4.85e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—BCHE—malignant glioma	1.97e-05	4.81e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—malignant glioma	1.97e-05	4.79e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CG—malignant glioma	1.96e-05	4.78e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BRAF—malignant glioma	1.95e-05	4.76e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC5A5—malignant glioma	1.95e-05	4.75e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NCOR1—malignant glioma	1.91e-05	4.66e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—malignant glioma	1.9e-05	4.64e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT2—malignant glioma	1.9e-05	4.64e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—malignant glioma	1.89e-05	4.62e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—malignant glioma	1.88e-05	4.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CD—malignant glioma	1.83e-05	4.45e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—malignant glioma	1.82e-05	4.43e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—IDH1—malignant glioma	1.82e-05	4.43e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.82e-05	4.43e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—malignant glioma	1.8e-05	4.39e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	1.79e-05	4.37e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTP1—malignant glioma	1.79e-05	4.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SPHK1—malignant glioma	1.76e-05	4.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—malignant glioma	1.76e-05	4.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGF2—malignant glioma	1.75e-05	4.27e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CAT—malignant glioma	1.74e-05	4.25e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—malignant glioma	1.73e-05	4.22e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—malignant glioma	1.73e-05	4.21e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CD—malignant glioma	1.72e-05	4.2e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2C18—malignant glioma	1.72e-05	4.2e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—malignant glioma	1.67e-05	4.07e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NCOR1—malignant glioma	1.64e-05	4.01e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MDM2—malignant glioma	1.64e-05	3.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—malignant glioma	1.63e-05	3.98e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—malignant glioma	1.63e-05	3.98e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RAF1—malignant glioma	1.63e-05	3.98e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB2—malignant glioma	1.61e-05	3.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—malignant glioma	1.6e-05	3.89e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CB—malignant glioma	1.59e-05	3.88e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTP1—malignant glioma	1.57e-05	3.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CAV1—malignant glioma	1.56e-05	3.8e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—malignant glioma	1.53e-05	3.73e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—malignant glioma	1.53e-05	3.73e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CAT—malignant glioma	1.53e-05	3.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—malignant glioma	1.51e-05	3.68e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CB—malignant glioma	1.5e-05	3.66e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—malignant glioma	1.5e-05	3.66e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—malignant glioma	1.49e-05	3.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—malignant glioma	1.46e-05	3.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—malignant glioma	1.46e-05	3.57e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NCOR1—malignant glioma	1.44e-05	3.51e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CG—malignant glioma	1.42e-05	3.46e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—malignant glioma	1.41e-05	3.44e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—malignant glioma	1.41e-05	3.43e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTT1—malignant glioma	1.39e-05	3.4e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—malignant glioma	1.39e-05	3.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—malignant glioma	1.38e-05	3.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—malignant glioma	1.38e-05	3.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—malignant glioma	1.37e-05	3.34e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—malignant glioma	1.36e-05	3.32e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CAV1—malignant glioma	1.34e-05	3.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS1—malignant glioma	1.31e-05	3.18e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—malignant glioma	1.3e-05	3.17e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.28e-05	3.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CD—malignant glioma	1.25e-05	3.04e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—malignant glioma	1.24e-05	3.03e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—malignant glioma	1.23e-05	3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—malignant glioma	1.23e-05	2.99e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CG—malignant glioma	1.22e-05	2.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—BCHE—malignant glioma	1.21e-05	2.96e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.2e-05	2.92e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—malignant glioma	1.18e-05	2.87e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CAV1—malignant glioma	1.17e-05	2.86e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—malignant glioma	1.15e-05	2.8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—malignant glioma	1.14e-05	2.79e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—malignant glioma	1.13e-05	2.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—malignant glioma	1.12e-05	2.73e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CB—malignant glioma	1.09e-05	2.65e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—malignant glioma	1.08e-05	2.62e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CD—malignant glioma	1.07e-05	2.62e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CG—malignant glioma	1.07e-05	2.61e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—malignant glioma	1.06e-05	2.58e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—malignant glioma	1.03e-05	2.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—malignant glioma	9.71e-06	2.37e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTP1—malignant glioma	9.66e-06	2.36e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CD—malignant glioma	9.41e-06	2.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CAT—malignant glioma	9.4e-06	2.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—malignant glioma	9.39e-06	2.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—malignant glioma	9.39e-06	2.29e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CB—malignant glioma	9.36e-06	2.28e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—malignant glioma	9.27e-06	2.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—malignant glioma	9.16e-06	2.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOR1—malignant glioma	8.88e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CB—malignant glioma	8.2e-06	2e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—malignant glioma	8.12e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—malignant glioma	8.09e-06	1.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—malignant glioma	7.93e-06	1.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—malignant glioma	7.49e-06	1.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CAV1—malignant glioma	7.24e-06	1.76e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—malignant glioma	7.09e-06	1.73e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—malignant glioma	6.62e-06	1.61e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CG—malignant glioma	6.59e-06	1.61e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—malignant glioma	6.36e-06	1.55e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CD—malignant glioma	5.8e-06	1.41e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—malignant glioma	5.7e-06	1.39e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—malignant glioma	5.41e-06	1.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CB—malignant glioma	5.05e-06	1.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—malignant glioma	5.01e-06	1.22e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—malignant glioma	5e-06	1.22e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—malignant glioma	4.66e-06	1.14e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—malignant glioma	4.37e-06	1.06e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—malignant glioma	4.08e-06	9.96e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—malignant glioma	3.08e-06	7.51e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—malignant glioma	2.52e-06	6.13e-06	CbGpPWpGaD
